TrialJournal for immunotherapy of cancer2025

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.

Harry D Bear et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.